Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC)1 and OXB,1 today announce the start of LENTICLAIRTM 1, a Phase I/II trial of BI 3720931, a novel, first-in-class, gene ...
"But if you look at the most effective screening test we have, as far as number of lives saved or number of scans we have to ...
Ioana Bonta, MD, Georgia Cancer Specialists, discusses the evolving state of non-small cell lung cancer (NSCLC) treatments, their impact on patient outcomes, and the need to address ongoing ...
Respiratory diseases are a challenging problem to treat. Inhalable medicines are a promising solution that depend on the ability to deliver tiny particles known as aerosols to the correct location in ...
News Medical on MSN18h
Researchers find that blocking specific proteins in immune cells can reduce or reverse lung scarringA discovery at Duke-NUS Medical School offers new hope in the battle against pulmonary fibrosis, a debilitating lung ...
Researchers at the University of California San Diego have found an unusual ally in the quest to make cancer diagnosis faster ...
A discovery offers new hope in the battle against pulmonary fibrosis, a debilitating lung condition that progressively makes it harder for patients to breathe. Scientists have pinpointed proteins in ...
GlobalData on MSN21h
FDA grants priority review for Boehringer’s zongertinib NDA in NSCLCPriority review illustrates the urgent need in this patient population and the possibility for zongertinib to be a groundbreaking innovation for patients with limited treatment ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback